Financial Tearsheet

Company Overview

ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.

ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.

Recent Financial News

IR Contacts

MacDougall

Christi Waarich
Senior Director, Investor Relations
cwaarich@macbiocom.com
http://www.macbiocom.com/

Stock Performance

Today's Open 1.19
Volume 6,399
Day Range 1.15 - 1.23
52 Week Range 0.90 - 5.75
Bid/Ask 1.15 / 1.18
Bid/Ask Size 1,600 X 100
Previous Close 1.17
Market Cap 8.78 million
Shares Outstanding 7.42 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -1.705800
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Aug 08, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 11, 2019 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 05, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 13, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David R. Wells, Chief Financial Officer

Steve Freeman, Human Resources Leader

Board of Directors

Francois Michelon, Chairman of the Board

Anthony DiGiandomenico, Director

Dr. Sanjiv Sam Gambhir, Director

Michael Harsh, Director

Alexander Tokman, Director